Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | IDH2 | P48735 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710237 | 1.00 | SMYD3 (1.00) | SMYD3POLBHTTSIGMAR1MEN1 | |
| SCHEMBL19701393 | 0.89 | SMYD3 (0.80) | SMYD3POLBHTTSIGMAR1MEN1 | |
| SCHEMBL21489802 | 0.89 | SMYD3 (0.80) | SMYD3POLBHTTSIGMAR1MEN1 | |
| SCHEMBL9849509 | 0.87 | SMYD3 (0.77) | SMYD3POLBHTTSIGMAR1MEN1 | |
| SCHEMBL9849508 | 0.86 | SMYD3 (0.75) | SMYD3POLBHTTSIGMAR1MEN1 | |
| SCHEMBL6867356 | 0.78 | MEN1 (0.68) | SMYD3POLBHTTSIGMAR1MEN1 | |
| SCHEMBL23575873 | 0.76 | SMYD3 (0.61) | SMYD3SIGMAR1 | |
| SCHEMBL21490175 | 0.76 | SMYD3 (0.61) | SMYD3POLBSIGMAR1MEN1KMT2A | |
| SCHEMBL19710155 | 0.76 | SMYD3 (0.61) | SMYD3POLBSIGMAR1MEN1KMT2A | |
| SCHEMBL19710224 | 0.76 | SMYD3 (0.61) | SMYD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885POLB 4132/4885HTT 4022/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885POLB 4325/4885HTT 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.